The content is available as a PDF (93.1 KB).
Una primera versión de este trabajo se publicó en el boletín de la Asociación de Economía de la Salud, octubre de 2002, número 45
Bibliografía
- 1.Reventlow S., Hvas A.C., Tulinius C. In really great danger. The concept of risk in general practice. Scand J Prim Health Care. 2001;19:71–75. doi: 10.1080/028134301750235268. [DOI] [PubMed] [Google Scholar]
- 2.Holtzman M.A., Marteau T.M. Will genetics revolutionize medicineα. N Engl J Med. 2000;343:141–144. doi: 10.1056/NEJM200007133430213. [DOI] [PubMed] [Google Scholar]
- 3.Pérez Fernández M., Gérvas J. Encarnizamiento diagnóstico y terapéutico con las mujeres. Semergen. 1999;25:239–248. [Google Scholar]
- 4.Pérez Fernández M., Gérvas J. El efecto cascada: implicaciones clínicas, epidemiológicas y éticas. Med Clin (Barc) 2002;118:165–167. doi: 10.1016/s0025-7753(02)72283-5. [DOI] [PubMed] [Google Scholar]
- 5.Gérvas J., Pérez Fernández M. Las hiperlipemias y la prevención primaria de la cardiopatía isquémica. Med Clin (Barc) 1997;109:549–552. [PubMed] [Google Scholar]
- 6.Gérvas J. Screening for serious illness. Limits to the power of medicine. Eur J Gen Pract. 2002;8:47–49. [Google Scholar]
- 7.Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. Randomized trial of estrogen plus progestin for secondary pre-vention of coronary heart disease in postmenopausal women. Jama. 1998;280:605–613. doi: 10.1001/jama.280.7.605. [DOI] [PubMed] [Google Scholar]
- 8.Pastor A. Un hito histórico de la humanidad. El Mundo. 2003:4882–4884. [Google Scholar]
- 9.Smith K.C. Genetic disease, genetic testing and the clinician. Jama. 2001:285–291. [PubMed] [Google Scholar]
- 10.Melzer D., Zimmern R. Genetics and medicalisation. Bmj. 2002;324:863–864. doi: 10.1136/bmj.324.7342.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Beutler E., Felitti V.J., Koziol J.A., Ho N.J., Gelbart T. Penetrance of 845G-A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211–218. doi: 10.1016/S0140-6736(02)07447-0. [DOI] [PubMed] [Google Scholar]
- 12.Hirschhorn J.N., Lohmueller K., Byrne E., Hirschhorn K. A comprehensive review of genetic association studies. Gen Med. 2002;4:45–61. doi: 10.1097/00125817-200203000-00002. [DOI] [PubMed] [Google Scholar]
- 13.Haddow J.E., Bradley L.A. Hereditary haemocrhomatosis: to screen or not to screen. Bmj. 1999;319:531–532. doi: 10.1136/bmj.319.7209.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Voelker R. Hemochromatosis patients are untapped source of blood as war, shortages lomos. Jama. 2003;289:1364–1366. doi: 10.1001/jama.289.11.1364. [DOI] [PubMed] [Google Scholar]
- 15.Willis G., Jennigs B.A., Fellows T.W., Wimperis JZ. A high prevalence of HAL-H 845A mutations in hemochromatosis patients and the normal population in Eastern England. Blood Cells Mol Dis. 1977;23:288–291. doi: 10.1006/bcmd.1997.0145. [DOI] [PubMed] [Google Scholar]
- 16.Merryweather A.T., Worwood M., Parkinson L., Mattock C. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol. 1998;101:369–373. doi: 10.1046/j.1365-2141.1998.00736.x. [DOI] [PubMed] [Google Scholar]
- 17.McCune C.A., Al-Jader L.N., May A., Hayes SL. Worwood M. Hereditary haemochromatosis: only 1% of adults HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet. 2002;111:538–543. doi: 10.1007/s00439-002-0824-1. [DOI] [PubMed] [Google Scholar]
- 18.Willis G., Wimperis J.Z., Smith K.C., Jennings B.A. Haemochromatosis gene C282Y homozygotes in an elderly male population. Lancet. 1999;354:221–222. doi: 10.1016/S0140-6736(99)02195-9. [DOI] [PubMed] [Google Scholar]
- 20.Bentzen N., editor. WONCA dictionary of general/family practice [in press] Maanedskift Lager; Copenhagen: 2003. [Google Scholar]